Caring for Older Australians
Productivity Commission Issues Paper
30 July 2010
1. Executive Summary

This submission is in response to the release in May 2010 by the Productivity Commission of an Issues Paper: Caring for Older Australians. The Medical Technology Association of Australia (MTAA) welcomes the opportunity to comment on the paper and make specific recommendations. As a general comment MTAA would like to see policy developed to enable older Australians to have better access to medical products and technologies that assist independent living, decrease inappropriate emergency room and hospital admissions, and enable them to remain in their own homes for longer.

MTAA recommends:

- Provision of funding for an Essential Care List scheme to fund consumable medical items
- Provision of funding for technology for home and remote monitoring of medical conditions (Telemonitoring).

This submission makes specific response to the question posed on Page 26 of the Issues Paper: How might technology be used to enhance the care of older Australians? There are a large number of sub-acute medical products and remote monitoring devices that can assist elderly Australians to stay in their homes. While these are funded in other countries, current funding mechanisms in Australia are ad hoc. Advanced medical technologies can be used to monitor and maintain health remotely, however healthcare professionals are not currently reimbursed to take advantage of these benefits.

2. About the Medical Technology Association of Australia and the medical technology industry

The Medical Technology Association of Australia (MTAA) represents the manufacturers, exporters, importers and distributors of medical technology products in Australia. Medical technologies are products used in the diagnosis, prevention, treatment and management of disease and disability. Products range from commonplace, everyday items such as bandages and syringes, to high technology items such as cochlear implants and cardiac defibrillators and diagnostic imaging equipment.

The medical technology industry manufactures many products that contribute to the health of older Australians. These include devices to manage cardiac disease, diabetes and chronic obstructive pulmonary disease (COPD), as well as a range of devices that can be used to monitor patients in their homes (e.g. implantable cardiac defibrillators, implantable loop recorders, personal alarms, sensors, heart rate and other vital signs monitors, pressure sensors, enuresis sensors, scales, glucose monitors, blood pressure monitors, sub-acute medical products etc). The medical technology industry had sales in Australia of more than $7 billion in 2008/2009 and employs more than 17,500 people. It is strongly research-based, often working closely with healthcare professionals to design and develop products for improved patient benefit.
3. Comments on the Productivity Commission Issues Paper

The Issues Paper: Caring for Older Australians makes reference to a number of facts about our ageing population that are relevant to the provision of medical consumables and telemonitoring services. Firstly, the prevalence of chronic diseases is rising with the changing demographics of the Australian population, secondly there is a preference for independent living, and finally there have been improvements in care technologies (which must be funded).

The Commission addresses the challenges that Australia will face in order to provide healthcare services for an ageing population. By 2050 Australia will see the number of people aged 65-84 years double and the number of people aged over 85 quadruple (Australian Intergenerational Report, 2010). Forecasts by the National Health and Hospitals Reform Commission (2009) state that the number of aged care places will need to double by 2030 in order to meet demand. Current spending on aged care is currently 0.8 percent of GDP and is expected to more than double by 2049-50. An additional strain on the healthcare system is a shortage of informal care-givers, nurses (Isbister, 2009) and doctors (Joyce et al., 2006).

The Commission also outlines the need to address the issues of people living in rural and remote communities. Rural Australians have poorer health and access to fewer health services. Mortality rates increase with remoteness and people in remote areas make greater use of hospital emergency departments than primary care facilities. They also have the highest rates of potentially preventable hospitalisations, due to inequitable access to health services, medical consumables and medical technology (AIHW, 2009).

There are a number of medical technologies that meet the challenges associated with providing healthcare to ageing and remote populations. Advances in medical and information technology will fundamentally change the way that services are delivered to older Australians and those in remote communities. Older people wish to remain in their homes for as long as possible and there are a number of assistive living, communication and health-monitoring technologies that can delay or stop transition into residential care. Health professionals are not currently reimbursed if they wish to use these technologies to assist patients with independent living.

4. Establishment of an Essential Care List (ECL)

4.1. Background

This section addresses a key reform area – the development of an Essential Care List (ECL) to ensure that sub-acute care medical products needed by patients for their care, and in some cases, survival, are readily available using a system that is equitable, transparent, and affordable. The scheme for an ECL will enable subsidised access to essential care medical technologies that provide necessities to chronically ill or incapacitated patients in the community setting. The items intended for inclusion in the scheme are consumable, single use, non-implantable medical products, together with the hardware that the consumables are used with, essential to maintain an acceptable quality of life for afflicted patients who without government subsidy would not have adequate access to life supporting medical technology.

At present many of these essential care items are either unfunded or, if funded, vary in availability and subsidy depending on the place where the patient lives. Some
assistance is available from the Federal Government; other support is from State Governments. Some products are provided ex gratia by healthcare practitioners who understand the need of the patient for the benefit that can be gained from use of a particular product.

The National Health and Hospitals Reform Commission in its 2008 *Interim Report* recognized the deficiencies in this area of patient care. It states that “the patchwork of safety nets, including different eligibility rules and requirements for different services, is not compatible with a high-performance, productive health system, where the right services are provided to the right person at the right time” (page 308).

MTAA acknowledges the need to provide a robust framework to ensure that the system does not become too complex or expensive. There are several key issues to consider in scoping the scheme. There are also some useful lessons that can be learned from the review by the Department of Health in the UK of Part IX of the Drug Tariff.¹ MTAA’s conception of an Australian scheme is that it will operate similarly to a very simplified Pharmaceutical Benefit Scheme. While many of the products likely to be included in the scheme do not require a health technology assessment, there are some products which lend themselves to differential pricing based on additional patient benefit to attract an uplift on the base level or benchmark price.

MTAA has consulted widely on the possible structure and operation of the scheme. Bodies consulted were:

- Aged Care Association Australia
- Australian Council of Stoma Associations
- Australian Medical Association
- Australian Nursing Federation
- Australian Practice Nurses Association
- Australian Wound Management Association
- Consumer Health Forum
- Continence Foundation
- Continence Nurses
- Kidney Health Australia
- Pharmacy Guild of Australia
- Royal District Nursing Service (Vic)
- Royal Australian College of Surgeons

With the exception of patients who currently benefit from subsidized access to ostomy products through the Stoma Appliance Scheme, and the suppliers who support the patients, the proposed scheme has received universal support. The current Stoma Appliance Scheme (SAS) has operated since 1974 and is mandated under section 9A of the *National Health Act*. The SAS is integrated into a wide range of community-based support for persons with an ostomy.

The ECL policy is currently under review by the Department of Health.

### 4.2. Issues for consideration

There are several key issues for consideration in shaping the scheme:

- Entry point into scheme

¹ UK Drug Tariff Part IX established under Section 41 of the NHS Act 1977.
• Product range
• Current Australian Government funded schemes
• Pricing
• Delivery mechanisms

4.3. Entry point into the scheme

Assessment by a healthcare professional is an essential element to ensure that the correct product is identified for the patient need. There is also an ongoing need to correctly assess patient demand from the wider perspective of related health needs.

Listing of products on the ECL will allow appropriately authorised, qualified and credentialed healthcare professionals to prescribe or establish an entitlement to ECL items for all clinically eligible Australian patients in the community setting. It is not proposed to limit patient access according to status (whether privately insured or not), income, age or any other discriminator but neither is it proposed to exclude co-payments. It may be that a means test is appropriate to determine the level of co-payment. The eligibility of patients should be based on clinical criteria, developed in consultation with the broader community of healthcare stakeholders.

Products listed on the ECL may also be available through other pathways without assessment, but in these circumstances they would not be funded under the scheme. The patient’s entitlement to a product with a subsidy would require at least an initial assessment by a healthcare professional followed with appropriate subsequent assessment. The subsequent assessment ensures that the healthcare professional can determine appropriateness of treatment and familiarise a patient with any new product.

The following criteria are proposed for products to be listed on the ECL:

• Products are essential to the patient’s quality of life or survival, in all settings outside hospitals including the community setting and residential care
• Products should be capable of self administration or administration with the help of a carer or, if required, by a relevant healthcare professional (which would include home visiting nurses)
• Products must be safe and efficacious and, where regulated, included on the Australian Register of Therapeutic Goods (ARTG)
• Products are appropriate for prescribing in the community setting
• Products are clinically effective – required levels of clinical evidence will be higher where similar products have not been listed before or where a manufacturer or supplier seeks a higher price than for similar products already listed
• The cost of the product is relative to its clinical effectiveness.

Entry of products into the scheme will need to be determined by an appropriate assessment body, in particular if the product is a new category of product, or is at the margin of existing listed products. In assessing quality of life, there are many potential measures including the social outcomes such as whether the patient is able to remain in their own home, and have the capacity to engage socially.

Many of the products will have limited clinical data. The assessment body should issue guidelines to ensure that an application is appropriately supported.
4.4. Product range

In general the products contemplated by the scheme can be characterised as aids for daily living that are for the critical care of a patient or that improve the quality of a patient’s life. These will often be consumable items that are low technology. In some cases however they may be durable products, and may involve much higher levels of technology sophistication. The product range will also include the hardware that is supported by the consumables.

The scheme requires flexibility and redundancy to ensure that the range is not limiting but also that it does not grow to a disproportionate size. The scheme requires a methodology by which other items can be added. There also needs to be a mechanism by which products can be removed from the ECL. There is some natural redundancy in that suppliers will withdraw products that are out of date or superseded. However there are some circumstances where patients continue to use products long after they have been superseded because of familiarity and confidence in the older product. To this extent there may need to be capacity to maintain availability of small numbers of otherwise redundant products.

Budget 2010/11 Portfolio Outcome 2 for the Department of Veterans Affairs (DVA) refers to entitled individuals having access to services that “maintain and enhance the physical wellbeing and quality of life through health and other care services that promote early intervention, prevention and treatment, including advice and information about health service entitlements”. The objective of DVA programs is to support veterans to remain independent in their homes, improve their quality of life and health and delay entry into residential aged care. The Repatriation Pharmaceutical Benefits Scheme (RPBS)\(^2\) and the Rehabilitation Appliance Program (RAP)\(^3\) are instructive for the range of products accessed by entitled individuals to meet the aims of support in the community to be as independent and self-reliant as possible in their own home. Product ranges covered by the schemes are comprehensive and fall into the major categories of: pharmaceuticals and wound dressings (RPBS); continence, diabetes, oxygen and continuous positive airways pressure (CPAP), mobility and functional support (MFS), and personal response systems (through the RAP). It is not proposed that non-medical products be available through the ECL; however DVA objectives, entitlement and prescribing guidelines are informative in the development of ECL parameters.

Products identified in an initial scope of the scheme include:

- Oxygen supplies/consumables
- Compression hosiery, bandages and garments for lymphodaema
- Continence products
- Modern wound care devices (including wound dressings)
- Breast prosthetics (non-implantable)
- Pumps and consumables for insulin delivery, and continuous flow pumps for drug delivery, together with consumables
- CPAP/sleep apnoea devices
- Laryngitic products
- Diabetes consumables (pens, strips, pump consumables)

\(^2\) The RPBS provides a wide range of pharmaceuticals and dressings at a concessional rate for the treatment of eligible veterans, war widows/widowers, and their dependants.

\(^3\) The RAP assists veterans, war widows and widowers and dependants to be as independent and self-reliant as possible in their own home.
• Home dialysis devices, consumables and set-up costs.

As many patients will have their first exposure to a product as a consequence of hospitalisation, there may need to be a mechanism to ensure a broader availability of products in the hospital system, as well as ongoing access to products introduced to the patient in hospital where these are judged most appropriate.

4.5. Current Australian Government funded schemes

Of the products identified above, continence and diabetes consumables are funded through schemes established by the Australian Government, in addition to ostomy products. Approximately 910,000 persons benefited from services and consumables provided under the National Diabetes Services Scheme (NDSS) in 2008/2009. The products are provided to people registered with NDSS through Diabetes Australia offices, by mail order and through accredited sub-agents such as pharmacies, hospital clinics and other outlets. Diabetes Australia also provides a range of educational and information services to assist in the best use of products and the effective self management of diabetes.

Products available through the NDSS include:

• Pen needles and syringes
• Special injection system needles
• Blood and urine glucose testing strips
• Insulin infusion pump consumables.

There are approximately 30,000 ostomates who receive support through the Commonwealth-funded Stoma Appliance Scheme (SAS). Ostomates receive products under the SAS through approved volunteer stoma associations. The stoma associations purchase stoma related products from suppliers and distribute to their members as required.

The Australian Government also provides a subsidy to eligible people through the Continence Aids Payment Scheme (CAPS). CAPS provides a direct payment ($489.95) to patients enabling them to shop around and identify the best value product for their needs. The level of subsidy is subject to indexation. Some states also provide top-up funding.

The total cost of the aids and appliances schemes funded by the Commonwealth in 2008/2009 was $195,032,000. The scope of products included in this figure is not disclosed but is assumed to include the three funded areas discussed above.

A list of states’ schemes is at Annex A.

There is inconsistent funding across Australia for modern wound care devices (MWCD). While most states do not fund MWCD some do, but to a limited extent (in South Australia and Western Australia dressings are provided to a limited degree by home nursing services). In NSW the NSCCAHS has subsidised MWCD on a trial basis.

---

basis in the Central Coast. Other products have varying levels of funding or subsidy. Where a product is not funded, patient access is limited to those with the capacity to pay, or at times, through the good graces of treating healthcare professionals.

In the 2009 Federal Budget the Government made a small but significant contribution to assist patients suffering from Epidermolysis Bullosa with a national dressing scheme worth $16.4 million over four years from January 2010. The scheme is administered by BrightSky Australia, a division of the Paraplegic and Quadriplegic Association of New South Wales, on behalf of the Australian Government.

4.6. Pricing

The scheme is not intended to be fully-funded, but requires a degree of patient co-contribution. MTAA estimates the amount in a range of $200-650m per annum, depending on the scope of included items. This sum is a combination of what is currently being spent in the various schemes across Commonwealth and State health budgets, plus additional areas that are currently unfunded. This amount does not take into account cost savings achieved through the merger of current stand-alone schemes. Costs and potential cost savings are outlined in Annex B and C. MTAA has calculated the costs of the scheme using both conservative and non-conservative figures. Conservative figures assume equipment rental and funding for consumable items only. Less conservative figures assume purchase of equipment such as CPAP machines, oxygen concentrators etc as well as provision of consumable items. It is likely that the true costs falls somewhere in between the two figures ($217m and $667m). Cost savings from the scheme could be as high as $250m. All cost savings are calculated with the assumption of an average DRG cost per separation and the assumption that approximately 9.3% of separations for chronic conditions are preventable. Cost savings generated by the ECL assume that the provision of sub-acute medical items will reduce Emergency Room and hospital admissions.

As at present with the identified products, there is a degree of patient co-contribution. The scope of the co-contribution will be dependent on the funding model adopted. For example, under current arrangements the co-payment by an ostomate is the fee to be a member of an ostomy patient association. The patient associations are run on a voluntary basis so the service provided by the associations has a cost equivalence.

One concern in imposing significant levels of patient co-payment for some products is an increase in patient non-compliance with the possibility that patients will reuse consumable products rather than replace them. There needs to be a mechanism by which products can be reviewed and reassessed as they date and no longer provide the additional patient benefit in comparison with competing products in the same group. Price review also needs to take account of longevity of product life cycles which means the development costs may be amortised over long periods of time.

The cost effectiveness assessment needs to be kept simple. However the analysis needs to be sufficiently robust to take account of societal factors, including both patient benefit and broader benefits to the Australian economy such as the capacity of a patient to engage in the workforce, remain in their home, or reduce dependence on a carer.

---

8 AIHW. Separation statistics for selected potentially preventable hospitalizations for chronic conditions for all states and hospitals, 2007-08.
A reasonable approach is to have one level of funding for ‘entry level’ which is a
generic price applied to all products within a product band within the scheme.
Additional reimbursement may be appropriate for a premium product which provides
improved product effectiveness on an evidence-based assessment. Any health
technology assessment should be by a professional independent body with the
capacity to conduct the clinical assessment of the claims made. A price review
mechanism should be incorporated to allow for changing circumstances (e.g. cost of
raw materials and oil) and consideration of CPI effects.

4.7. Delivery mechanisms

There are multiple delivery mechanisms for the products currently supplied under the
various schemes funded by the federal and State Governments. These include
consumer groups, pharmacists, healthcare professionals, contractors and
manufacturers/suppliers.

There are particular reasons why a ‘one size fits all’ solution may not be appropriate.
Consumer or patient groups provide more than simple product supply by offering a
support network and social connection that would not be available through traditional
supply routes such as pharmacies. The delivery of some products may be more
critical in certain circumstances and varied performance criteria for delivery may be
appropriate.

One option would be to consider multiple supply routes, with pharmacies as the
default in the absence of other appropriate supply mechanisms. The reimbursement
of the supply should be fixed to ensure that the scheme remains manageable – an
example is the scheme operated under Part IX of the Drug Tariff in the UK (see
paragraph 4.8.1 for a more detailed discussion). Supply costs should be an integral
component of the scheme to ensure that the cost to the consumer remains constant
and predictable regardless of location of the consumer and method of supply.

Other delivery options include by post, by relevant healthcare professionals (such as
home visiting nurses), through community pharmacies, or through appliance
contractors (as in the UK). Under the NDSS the same price point applies regardless
of whether the products are supplied by a pharmacy or by Australia Post. One issue
that may arise is the capacity of pharmacies to ensure an adequate stock of products
with low demand.

4.8. A review of other schemes

4.8.1. Part IX Drug Tariff (United Kingdom)

The Department of Health in the UK has undertaken a series of consultations to
review the structure and funding arrangements under Part IX of the Drug Tariff which
covers reimbursement for wound dressings, incontinence appliances, stoma
appliances and chemical reagents. Part IX had not been reviewed for 20 years. The
July 2010 Drug Tariff has recently been published9. To the extent that the scheme
addresses inclusion and reimbursement for several of the product groups proposed
for inclusion on the ECL, there is some valuable experience from which Australia can
draw. While the Drug Tariff is addressed to items in both primary and secondary
care, the larger part of the expenditure is in primary care which is the focus of the
ECL. In the primary care setting the items are prescribed by GPs and dispensed to

the patient through contractors such as pharmacy contractors and appliance contractors.

Items are provided by manufacturers and wholesalers to the contractors. Services to patients in primary care, such as telephone assistance, home visits and product customization are provided mainly through appliance contractors and funded through the reimbursement of items. In addition to services, some manufacturers, and in particular those that are vertically integrated, sponsor nursing posts and patient groups.

At Annex D is a diagrammatical representation of the supply chain in the UK.

The Department’s stated objectives in undertaking a review of the reimbursement arrangements were to:

- Maintain, and where applicable improve, the current quality of care to patients
- Secure value for money for the NHS
- Ensure equitable payment for equivalent services and transparent reimbursement pricing
- Work in partnership to deliver fair prices for the NHS and reasonable returns for suppliers and contractors
- Facilitate the introduction of innovative solutions
- Maintain local choice in the provision of services; and
- Keep administration arrangements to the necessary minimum.

These objectives (contextualised for Australia) all appear relevant and appropriate.

In subsequent consultations focused on stoma products and continence products further findings emerged. These include the fact that many users of incontinence appliances as well as stoma appliances rely on home delivery. Similarly patients who use catheters also require a home visit. As a consequence, the pricing was revised to take account of the additional services supplied by way of home visits and customisation of stoma appliance flanges.

In addition to a revised payment structure for items and services, the UK Department of Health also proposes establishing a code of practice for suppliers in partnership with patient groups. This is intended to address issues such as patient service specification, sponsorship of nurses and patient groups and the direct marketing of items to patients.

This objective would also be supported by MTAA as consistent with the MTAA Code of Practice.

The July 2010 Drug Tariff specifies the arrangements for products listed in Part IXA (catheter, tracheotomy, dressings, bandages, laryngectomy items), Part IXB (incontinence appliances) and Part IXC (stoma appliances). The arrangements differentiate between payment for services and reimbursement for items. Dispensing Appliance Contractors (DACs) and pharmacy contractors are required to provide a specified set of services for items they supply in the normal course of their business:

- A dispensing service
- A home delivery service for catheters, laryngectomy and tracheotomy prescription items listed in Part IXA of the Drug Tariff and for all items listed in Parts IXB and IXC prescription items, if so requested by the user
• Complementary supplies of wipes and disposal bags with some prescription items; and
• Dispensing both elastic hosiery that requires measurement and/or fitting and trusses requiring measurement and/or fitting.

In addition, DACs and pharmacy contractors may choose to provide advanced services:

• The customisation of stoma appliances and/or
• Appliance use reviews (AURs) which are intended to improve the patient’s knowledge and use of the appliance. The reviews will be conducted with the consent of the patient and are intended to complement the care provided by the healthcare professionals.

4.8.2. Repatriation Pharmaceutical Benefit Scheme

The Australian Repatriation system is based primarily on the principle of compensation to veterans and eligible dependants for injury or death related to war service.

Through the Veterans' Entitlements Act 1986 the Department of Veterans' Affairs provides amongst other things, treatment for eligible veterans and their dependants. One of the defined benefits for eligible veterans is the Repatriation Pharmaceutical Benefits Scheme. A comprehensive range of medications and wound dressings is available through the Pharmaceutical Benefits Scheme.

Unless otherwise stated, Repatriation Pharmaceutical Benefits Scheme (RPBS) prescriptions must conform with the requirements of Pharmaceutical Benefits Scheme (PBS) prescriptions. Users of the RPBS pay a co-payment considerably lower than users of the PBS. Eligible veterans receiving Special Pharmaceutical Benefits under the RPBS are required to pay only the concessional patient contribution and any applicable brand premium.

4.8.3. Rehabilitation Appliance Program (RAP)

The Rehabilitation Appliance Program is an Australian Government program, administered by the Department of Veterans’ Affairs, which provides aids and appliances to eligible members of the veteran community to help them maintain their independence as they grow older. The program provides safe and appropriate equipment:

• According to assessed clinical need;
• In an effective and timely manner; and
• As part of the overall management of an individual’s health care.

Equipment provided should be:

• Appropriate for its purpose
• Safe for the entitled person; and
• Designed for persons with an illness or disability, and not widely used by persons without an illness or disability.
4.9. Governance of the scheme

Consistent with all well-structured HTA bodies, the body which assesses products for inclusion on the ECL, and which sets the level of reimbursement, must be independent and qualified to make the assessments. It is appropriate to include representation of patient interests and industry interests as well as healthcare professionals and payers. It may be appropriate to use the HTA review mechanisms put in place as a result of the Review of the Health Technology Assessment, the recommendations of which were substantially accepted by the Government in February 2010. Assessments of clinical and comparative effectiveness should be undertaken by reference to appropriately qualified persons. These may be constituted in small clinical reference or assessment groups.

Decisions of the HTA body should be reviewable and appealable in circumstances where there has been a demonstrable error in a finding. The HTA body would also monitor the effectiveness of the scheme.

The body would be advisory in that the Minister for Health and Ageing will make the final decision on inclusion of a product and level of reimbursement.

5. Provision of Telemonitoring Services

5.1. Background

The Issues Paper: Caring for Older Australians asks a specific question relevant to telemonitoring and the medical technology industry (page 26):

“How might technology be used to enhance the care of older Australians?”

In 2007-08 health expenditure in Australia was $103.6 billion (9.1% of gross domestic product). Only 2% of this amount was for preventive services or health promotion ($20 million) (AIHW, 2010). Telemonitoring falls under the umbrella of tertiary prevention, which aims to slow the progress of diseases when they occur. Innovative technology and the clinical and cost savings associated with telemonitoring have demonstrated in a number of contexts, however the pace of innovation has been much faster than regulation, reimbursement initiatives and the speed at which new technology is adopted by clinicians and patients. In Australia, adequate reimbursement policies and guidelines are needed to before these technologies can be delivered to patients.

Telemonitoring encourages active self-management as patients are taught to monitor physiological indices such as blood glucose. Telemonitoring of vital signs uses equipment and medical devices installed in the patient’s home to identify trends and send alerts when necessary, in order to detect symptom exacerbations, intervene early and reduce hospital admissions. It is estimated that 35% of individuals living in care homes could be supported at home using telemonitoring (U.K. Department of Health, 2005).

There has been a shift in chronic disease management from acute care in hospitals to home or residential care. Telemedicine is the delivery of medical services through information technology, multimedia, imaging and telecommunications. It is an overarching definition that includes the discipline of telemonitoring. Telemonitoring (or remote patient monitoring) covers the exchange of medical data between a
patient who is at home and a healthcare professional based (usually) in a medical centre. The medical technology industry manufactures a range of telemonitoring devices including enuresis monitoring devices, personal alarms and alert systems, home units for measuring temperature, heart rate, blood pressure, glucose levels, oxygen levels and objective symptoms. Patient data are transferred to a monitoring centre using phone lines or wireless technology. In some cases devices may have a diagnostic (e.g. an implantable loop recorder) or assessment (e.g. bladder diaries) application or monitor symptoms associated with an undiagnosed condition (e.g. atrial fibrillation). Suitable conditions for telemonitoring include stable chronic diseases such as asthma, COPD, diabetes, cardiovascular disease, cardiac arrhythmias and dementia.

5.2. Social and health benefits of telemonitoring

The social and health benefits of telemonitoring can be summarised as:

- Reducing barriers of access to healthcare and decreasing disparities due to geography
- Providing access to specialists in areas where there is a shortage of specialist staff
- Reducing the pressure on an over-extended healthcare workforce
- Freeing up hospital beds
- Shifting responsibility for healthcare onto the consumer
- Promoting proactive rather than reactive healthcare
- Provision of a viable alternative to outpatient or doctor visits
- Reducing congestion in medical centres and emergency rooms
- Increasing quality of life
- Encouraging adherence to treatment regimes
- Reducing the burden on care givers
- Better integration of health and social services
- Increased access to patient care from a number of groups (carers, family, medical professionals)
- Early detection of abnormalities/symptom exacerbations
- Reducing the number of unnecessary hospital admissions.

5.3. Clinical benefits of telemonitoring

A large number of studies report a wide range of clinical benefits associated with telemonitoring, including reduced mortality, hospital admissions and readmissions, length of time in hospital, and critical care utilization. The clinical outcomes of twelve studies are summarised in Annex E. The largest study, to date, was undertaken by the Veterans Health Administration in the US, which analysed data from a national home telehealth program, Care Coordination/Home Telehealth (CCHT). The aim of the CCHT program is to avoid the unnecessary admission of veterans with long term chronic health conditions, into institutional care. The program aids people to live independently in their own home by implementing home telehealth, health informatics and disease management technologies. Patients are predominantly male (95%) aged 65 or older. Darkins et al. (2008) analysed data from a cohort of 17,025 patients and report:

---

10 Definition adapted from the European Coordination Committee of the Radiological, Electromedical and Healthcare IT industry (COCIR).
• A 25% reduction in numbers of bed days of care
• A 19% reduction in numbers of hospital admissions
• A mean satisfaction score rating of 86% after enrolment into the program.

Due to these impressive results, CCHT is now a routine program and provides services for hypertension, post traumatic stress disorder (PTSD), congestive heart failure (CHF), diabetes, COPD and depression. A care coordinator selects the appropriate home health technology, provides training, reviews data, communicates with the patient’s physician and provides active case management. Depending on the patient’s condition the care coordinator is able to select appropriate vital signs and other objective physiological data (e.g. heart rate, glucose levels) to monitor. An algorithm is used to determine the most appropriate device to use. Peripherals include: messaging devices (which present disease management protocols), videophones (that allow for remote consultations), digital cameras and biometric devices (to monitor vital signs). Patients are risk-stratified each day according to predetermined thresholds (e.g. increased heart rate). Medical staff intervene if there are any problems, rather than patients delaying treatment or presenting at the emergency room. A care coordinator is able to manage between 100-150 general medical patients.

5.4. How telemonitoring can advance the Australian healthcare system

There are 2.8 million Australians over the age of 65 years (~13% of the population in 2008) (AIHW 2009), coupled with a shortage of care givers and facilities. The conditions best suited to telemonitoring include many of those which are more prevalent with age. Coronary heart disease was the leading specific cause of death for both males and females in 2007-08. In 2009, circulatory diseases, such as heart disease and hypertension, were the most common physical ailments among older permanent residents living in residential aged care facilities (DoHA ACCMIS database). These types of chronic conditions are well suited for telemonitoring. Telemonitoring services will ease the burden of current demands on the Australian health system. Remote monitoring increases staff efficiency (Alwan et al., 2007) and decreases the number of nursing home visits and the amount of travel time (Litzinger et al., 2007). It also reduces the demand on emergency rooms and hospitals.

Australia is already a world leader in the provision of unique medical care to remote communities. The Royal Flying Doctor Service11 provides over 85,000 consultations a year. Remote consultations are provided 24 hours a day, 7 days a week to patients in remote areas. Most consultations are provided over the telephone; however radio or videoconferencing is also used. Health professionals are able to conduct assessments, deliver treatment advice and monitor conditions to determine whether follow-up at a remote clinic or aerial evacuation are necessary.

There is an inequity in the provision of chronic heart failure (CHF) management programs in rural Australia. Approximately 20% of individuals with CHF live in rural and remote areas, while 93% of CHF management programs are located in capital cities or metropolitan areas (Clark et al., 2007). If policy were developed and medical professionals adequately reimbursed, remote monitoring could be used to increase the access to patient care in these regions.

Telemonitoring, in particular consultations via video conferencing, provide a way of providing services to people in rural and remote regions. In 2004-06 death rates in

‘very remote’ areas were 1.8 times as high as major cities (some of this increase can be explained by the high proportion of indigenous people living in remote areas). People in remote regions make greater use of hospital emergency departments than primary care facilities. In 2004–06, there were about 4,600 excess deaths per year outside major cities, i.e. deaths above the number expected if these areas had the same death rates as major cities. The main causes of death contributing to this excess were coronary heart disease (20%), ‘other’ circulatory disease (17%), and COPD (9%). Again, stable chronic conditions, prevalent in the elderly and suitable for home monitoring.

6. Issues for consideration

There are several key issues for consideration in providing patient access to telemonitoring:

- Suitability of patient
- Product range
- Current Australian Government funding and pilot projects
- Pricing
- Delivery mechanisms

6.1. Suitability of patient

Patients would need to be assessed by a health professional to ensure that they are assisted using the correct technology. Eligibility may be determined by current Aged Care Assessment Teams (ACATs), who determine eligibility for subsidised community care. It may be that a means test is appropriate to determine the level of co-payment if required. The eligibility of patients should be based on clinical criteria, developed in consultation with the broader community of healthcare stakeholders.

6.2. Product range

In general the products can be characterised as devices that monitor symptoms, detect exacerbations and assist patients to remain independent in their own home. The provision of telemonitoring services requires flexibility and redundancy to ensure that the range is not limiting to new and improved technologies but also that it does not grow to a disproportionate size. A methodology would be required, by which other items can be added and removed.

Products identified in an initial scope of the proposal include:

- Glucose monitoring devices used by insulin dependent diabetics
- Electrocardiogram (ECG) and mobile telecardiology systems for monitoring cardiac arrhythmias
- Home haemodialysis monitoring systems
- Wireless devices combining satellite global positioning systems (e.g. for dementia patients who wander)
- Home monitoring devices for pulse oximetry, blood pressure, heart rate, heart rate variability, epilepsy, spirometry, and weight monitoring
- Portable anticoagulation monitors
- Smart incontinence management systems, enuresis devices, and remote monitoring of continence events
- Remote monitoring and assistance for cochlear implantees
• Alarm systems to monitor falls and other medical alerts
• Videoconference consultations.

6.3. Current Australian Government funded schemes

At the level of the Federal Government, little policy work has been done to develop telemonitoring in Australia. A small number of devices that fit under the telemonitoring umbrella are funded in an ad-hoc way. For example, individuals who are eligible for Department of Veterans Affairs assistance may apply under the Rehabilitation Appliances Program (RAP) for a personal response system. The Victorian Government funds ‘Personal Alert Victoria’ (PAV), a personal monitoring service that responds to calls for assistance 24 hours a day. A small number of items are funded by Private Health Insurance and are listed on the Prostheses List (e.g. cardiac interloop recorders and defibrillators). In these cases the device is funded and the monitoring capabilities tend to be a free or unfunded adjunct. Currently there is no policy that outlines how doctors and allied health professionals should be reimbursed for remote monitoring of data.

At the State Government level there are funded initiatives to develop integrated models of care for chronic disease. An example is the Hospital Admission Risk Program (HARP) which is funded by the Department of Human Services in Victoria. HARP has developed preventive care models for individuals with chronic conditions (diabetes, respiratory disease and heart disease), who frequently utilize acute hospital services. The program identifies and manages at-risk patients, promotes self management, provides collaboration between existing services and reduces episodes of hospitalization. Care is tailored to the individual and enables them to stay in their homes for longer. HARP has been expanded into rural and regional health services across Victoria. Victoria also provides funding for video-conferencing and slit-lamp technology to image the eye. This means that patients do not need to travel to Melbourne for specialist remote ophthalmology services.

Queensland Telehealth funds services so that patients in remote locations can see a health professional from any hospital in Queensland, without the need to travel large distances. Patients visit a health facility and a nurse may take preliminary data readings prior to a videoconference. Patients get the same standard of treatment they would from a face-to-face appointment, at no additional cost.

There are a number of small pilot projects running in rural Queensland. The Centre for Online Health has developed a mobile, wireless telemedicine system that delivers consultations via a robot. They have also designed a system for tele-ENT, whereby real-time video images of a patient are transmitted via videoconference (Smith et al., 2006). Similarly, telemonitoring has been used to monitor post-laryngectomy patients in Queensland in a trial that took place over 1700kms using a 3G network and multimedia videoconferencing (Ward et al., 2009).

6.4. Pricing

Telemonitoring services are not intended to be fully-funded. The scope of the co-contribution will be dependent on the funding model adopted. It is likely that components such as monitors and some peripheral devices (e.g. scales, blood pressure monitors) can be rented and remain the property of the supplier. Other consumables may be disposable. Reimbursement of health professionals should be

aligned with current payment for traditional face-to-face consults and follow the same sets of principles outlined in the Medicare Benefits Schedule.

There needs to be a mechanism by which products can be reviewed and reassessed as they date (this type of technology is likely to change rapidly). Pricing may work according to similar principles outlined under the ECL scheme. In the absence of evidence or comparative data for specific monitoring systems, expert consensus should be taken into account.

6.5. Cost Benefits of Telemonitoring

For telemonitoring to be cost effective it must be able to provide equal or better medical care, at a lower cost than standard care. Evidence from seven pilot programs points to four factors that drive the success of home monitoring (Fields et al., 2010):

- Dedicated non physician care managers
- Expanded access to healthcare providers (e.g. ensuring a patient can have a medical question answered in the evening or weekend, rather than presenting to the emergency room)
- Performance management tools
- Payment incentives (i.e. member per month payments to physicians).

The outcomes from seven pilot programs are presented below. Home monitoring led to a reduction in hospitalizations, reduced emergency room visits and a decrease in costs.

Annual Outcomes for Seven Medical Home Demonstrations (Fields et al., 2010).

<table>
<thead>
<tr>
<th></th>
<th>Hospitalization reduction (%)</th>
<th>ER visit reduction</th>
<th>Total savings per patient ($US)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorado</td>
<td>18</td>
<td>-</td>
<td>$169-530a</td>
</tr>
<tr>
<td>Geisinger</td>
<td>15</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Group Healthb</td>
<td>11</td>
<td>29</td>
<td>$71</td>
</tr>
<tr>
<td>Intermountain</td>
<td>4.8-19.2c</td>
<td>0-7.3d</td>
<td>$640</td>
</tr>
<tr>
<td>North Carolina</td>
<td>40f</td>
<td>16</td>
<td>$516f</td>
</tr>
<tr>
<td>North Dakota</td>
<td>6</td>
<td>24</td>
<td>$530</td>
</tr>
<tr>
<td>Vermontg</td>
<td>11</td>
<td>12</td>
<td>$215</td>
</tr>
</tbody>
</table>

Sources: Colorado Department of Health Care Policy and Financing. Geisinger Health System, Notes 12-15 in text; Care Management Plus; Community Care of North Carolina; and Vermont BluePrint for Health. NOTES Not all metrics reported. Unless indicated otherwise, data are based on as-reported outcomes, reduction from baseline. ER is emergency room. a$169 for all patients; $530 for patients with chronic conditions. bChange relative to control group. See Note 12 in text, p. 2998, for more detail. c4.8 percent for all patients; 19.2 percent for patients with complex illnesses. dNo change for overall population; 7.3 percent for patients with complex illnesses. eOnly for asthma patients. fBased on Aid to Families with Dependent Children (AFDC) program savings from fiscal year 2007 ($135 million) and Aged, Blind and Disabled (ABD) program savings from fiscal year 2008 ($400 million). gExpected.

6.6. How might cost savings be achieved?

Page 20 asks: *Is there any evidence which suggests that the provision of greater choice may have resource implications?* (page 20).
Cost savings will vary depending on the technology selected and the patient group. A recent report, Smart Technology for Healthy Longevity, by the Australian Academy of Technological Sciences and Engineering (ATSE) covers the need for ‘ageing-in-place’ policies and outlines the potential for smart technology to deliver substantial cost savings in Australia. Dr Kim Sweeney (Centre for Strategic Economic Studies, Victoria University) reviewed the economic benefits of interventions that enable ageing-in-place. He estimated potential cost savings to the Australian Government of up to $526m per year. The following assumptions were used. Residential care is provided to 160,000 Australians per year at a cost $36,100 per annum. The Home and Community Care (HACC) program assists 650,000 Australians each year at a cost of $2,600\(^{13}\) (or $9,500 for Community Aged Care Package (CACP) clients). If a person is able to remain in the community receiving HACC, there is a cost saving to Government of $33,500 (or $26,600 if receiving CACP). Large cost savings can be generated if a proportion of individuals currently in residential care can be supported in the community using smart medical technologies. If 10% of the current residential care population (around 15,700 people) were able to be assisted in their homes using HACC, the cost saving to Government would be approximately $526m per year (or $426m for CACP clients). The review does not take into account the costs of peripheral devices and monitoring, or any cost savings associated with reduced Emergency Room visits, doctor visits or hospitalizations.

Economist Robert Litan has reviewed a range of studies to estimate cost savings in the US. He concludes that telehealth-enabled care management is most advantageous in patients with chronic conditions where changes in vital signs signal the need for medical intervention. Litan (2008) based his analysis on resource utilization and estimates that the US could generate net savings of $197 billion dollars (an improvement of 29% compared with continuation of current policy) over 25 years through telemonitoring of patients with chronic disease. His review found mixed results on the impact of telemonitoring on GP and outpatient visits, large decreases in emergency room visits, hospital and nursing home admissions and nursing home bed days of care. There were many quality of life benefits with remote monitoring including increased sense of security, avoidance of delayed treatment, reduced travel, and the means to remain in the home.

A large number of studies have shown that telemonitoring is cost effective. Outcomes from eleven studies are presented in Annex F. Veraga Rojas and Gragnon (2008) reviewed 23 studies assessing cost effectiveness to determine the direct and indirect costs of telemonitoring. Direct cost savings can be achieved as a result of:

- Reducing the number of clinical visits
- Reducing the distance travelled by healthcare professionals
- Early detection of symptom exacerbations and early intervention
- Reducing the number of emergency room visits
- Reducing the number of hospital re-admissions and bed days
- Decreasing the need for residential care.

Indirect cost savings can be achieved as a result of:

- Decreasing patient travel
- Increased patient and carer productivity
- Increased quality of life.

\(^{13}\) All costs are calculated per client per annum
In many cases, assistive technologies such as alarms, global positioning devices and electronic medication reminders, mean staff can spend less time doing routine monitoring and more time on direct patient care. Targeting high utilization patients is more likely to achieve cost savings. Programs such as CCHT in the US allow for interventions to be provided to patients before they deteriorate and need to be hospitalized. These programs do not replace the need for nursing home care, rather they enhance the ability for self management, offer a way to maintain independence and delay institutionalization. The CCHT study reported that the cost of monitoring a patient per annum was $1,600. This cost is far lower than either the direct cost of primary care services ($13,121) or care provided in a nursing home ($77,745).

7. Funding mechanisms

There are two cost considerations for the funding of telemonitoring. The first is the cost of the service (education, care provision, data transmission and data monitoring) and the second is the cost of devices (including monitors, hardware, software and medical devices). Telemonitoring services could be funded under the Medicare Benefits Schedule and/or community care packages, with a contribution from Private Health Insurance for devices for privately insured patients. Reimbursement strategies must be flexible enough to keep pace with the rapid technological advances associated with both wireless and medical technology. In the future telemonitoring will move beyond the telecommunications-only paradigms to fully integrated systems of in-home and in-hospital monitoring, data integration, electronic health records and physician/patient exchanges.

7.1. Funding under the Medicare Benefits Schedule (MBS) ¹⁴

Telemonitoring services (with the exception of telepsychiatry) are not currently funded under the Medicare Benefits Schedule (MBS). A doctor would need to find the most appropriate item number to cover a service. In most cases, there is no item number and a doctor must fit the service within an existing item number.

Currently data collected remotely can be monitored in a number of ways:

- the patient may be able to review it themselves (in which case no reimbursement is required)
- the patient may be able to share the report as part of a regular face-to-face consult, in which case MBS item numbers 110, 116, 119 may be used by a consultant physician
- the patient can share the report with their health care providers and the consultation with the multi-disciplinary team can take place as part of Case Conferencing, often by teleconferencing, in which case MBS item numbers 820-838 may apply. Case conferences apply to community or residential care conferences organized to discuss a patient in detail. Items apply to patients who suffer from chronic conditions and have complex care needs, requiring care from a multidisciplinary team. Formal care providers from a number of allied health professions may be included.

All services within the MBS book have a unique item number, description and Schedule fee/Medicare benefit. Benefits can be claimed for ‘clinically relevant’ services. Current MBS codes do not translate to remote monitoring consultations.

¹⁴ The Medicare Benefits Schedule (MBS) Book (Australian Government, Department of Health and Ageing, operating from 01 May 2010).
There are no items under the headings telemonitoring, telemedicine, teleradiology, home monitoring or remote monitoring. Telephone consultations do not attract benefits (with the exception of telepsychiatry). Telemonitoring items could be included under Category 1 (Professional Attendances) or 2 (Diagnostic Procedures and Investigations).

The rules applicable to Category 1 telepsychiatry services could be applied to telemonitoring. For example, the psychiatrist is responsible for keeping a record of episodes of care provided; there are limits to the number of consultations per year; and the consultant must use an outcome tool where clinically appropriate. The consult may include a mental state examination, a psychiatric diagnosis and the provision of a management plan. Telepsychiatry services have specific item numbers and are available for patients in regional, rural or remote areas. Remote areas are defined under the Rural Remote Metropolitan Areas classification system (RRMA 3-7), which describes the areas of medical practice within Australia and divides the rural, remote and metropolitan areas according to city status, population, rurality and remoteness.

Category 1 includes benefits for Chronic Disease Management (CDM). These items are comprehensive and enable evidence-based management of needs and are available for patients who have chronic medical conditions or complex care needs. They are used by General Practitioners (GPs) for:

- GP Management Plans (GPMP)
- Coordination by a GP of Team Care Arrangements (TCAs)
- Review by a GP of a GP Management Plan (GPMP)
- Coordination by a GP of a review of Team Care Arrangements
- Contribution to a multidisciplinary care plans (in the home or care facility).

Benefits are available for certain services provided by allied health professionals to people who are being managed by a GP using CDM items (721, 723, 729, 732). These cover in-patients and patients in the community or residential aged care facilities. Telemonitoring services would fit under remote management, monitoring and treatment of patients with chronic diseases needing complex care. A chronic medical condition is defined as one that has been (or is likely to be) present for least 6 months, e.g., diabetes, cancer, asthma, stroke, cardiovascular illness and musculoskeletal conditions. Telemonitoring Items would provide medical rebates for GPs or other allied health professionals who develop care plans, educate patients and monitor data. The item numbers would need to be flexible enough to include nursing staff or staff monitoring. Additionally, some telemonitoring items would fit under Category 2: Diagnostic Procedures and Investigations, for example implantable loop recorders.

In the US most telemedicine providers bill as usual and do not use modifiers or specialized CPT codes. Service providers considered telemedicine services in the same way they would face-to-face medical practices. In general, ‘special coding’ systems are considered counter productive.

Revisions to the MBS Quality Framework will introduce time-limited listing for new MBS items that do not undergo a Medical Services Advisory Committee (MSAC) assessment and the evaluation of these items. Under the MBS Quality Framework telemonitoring items may not need assessment through MSAC. In most cases, the medical devices used for home monitoring are the same as those used in traditional
consultations, with the addition of wireless technology and data transfer/monitoring capabilities.

7.2. Funding under Community Care Packages

The Productivity Commission (2008) addressed the need to unbundle residential care costs (i.e. accommodation, everyday living and personal care costs) to determine underlying costs and target those in need in a more equitable manner. Under the current system older people have problems accessing multiple services in order to continue living independently. Those who wish to transition between related systems (e.g. from hospital to home or to a residential care facility) face difficulties. Choice is often limited due to inconsistent funding arrangements between residential and community care programs (Bruen, 2006). Community care recipients are responsible for accommodation and any hotels costs, meaning that some elderly are virtually forced to enter residential care in order to receive accommodation subsidies (Kendig & Duckett, 2001). This has led to a financial bias towards residential care.

The majority of aged care in Australia is community based and elderly people receive aged care services in their home or in aged-care accommodation such as retirement homes. Telemonitoring could be included in current funded programs designed for individuals who are eligible for residential care – but prefer to remain in the community. The Australian government funds three packaged care programs designed for people who are eligible for residential care but who choose, with support, to remain in the community (below)\textsuperscript{15}. Eligibility is determined by Aged Care Assessment Teams (ACATs).

- The aim of Home and Community Care (HACC) services is to reduce inappropriate admissions to residential care by assisting people to remain independent in their own homes. Services are provided to around 650,000 people over the age of 70 per year, with most clients (90%) receiving less than two of hours of service per week. HACC provides low intensity levels of support to the elderly and people with disabilities. These include home modifications, personal care, domestic help and assistance by allied health care professionals.

- Community Aged Care Packages (CACPs) support older people with significant care needs to remain in their own homes or retirement villages. Around 5-6 hours of direct assistance per week are provided as an alternative to low level residential care. Assistance includes: home help; mobility; transport; personal hygiene; preparing meals; gardening; sensory communication, or fitting sensory communication aids; control and administration of medication; rehabilitative support; administration of specific treatments; and other services required to maintain the person at home. CACP support services include on-call access 24 hours a day to at least one approved person or agency in reasonably close proximity to the recipient who will organise emergency assistance if necessary.

- Extended Aged Care at Home (EACH) and Extended Aged Care at Home Dementia (EACH-D) packages provide 15-20 hours of support per week. These packages provide high levels of care in the home and include nursing care. EACH care providers are funded at $AUD110/day, which is the equivalent to the level for high care patients in residential care. Packages can include nursing and allied health care, social support, transport, home help, personal care and assistance with oxygen and/or enteral feeding.

\textsuperscript{15} Department of Health and Ageing, 2009.
In addition to the above packages, flexible care is aimed at addressing residential care needs. These include transition care (services provided either in the home or in a residential care setting for up to 12 weeks after a hospital stay), Multi-Purpose Services (for integrating health and aged care services in rural and remote areas depending on geography and need), and innovative care (a platform for testing new approached to providing care). Care in residential accommodation can be low or high level. Low level care provides assistance with accommodation and activities of daily living (e.g. mobility), while high level care provides nursing services, equipment (e.g. oxygen) and other complex care needs. Funding in residential care units is assessed using the Aged Care Funding Instrument (ACFI).

8. A review of other schemes

8.1. USA: Centers for Medicare and Medicaid

“*What lessons should the Commission draw from previous reforms of aged care systems (in Australia and overseas) to minimise adjustment costs faced by older Australian and their carers, providers, aged care workers and governments of moving to a new system?*” (page 26).

One of the major barriers to the wide spread adoption of telemonitoring is lack of reimbursement. The United States has overcome this barrier and remote monitoring has been approved by the Centers for Medicare and Medicaid (CMS) for reimbursement. In 2000 Congress passed the Benefits Improvement Act (BIPA), which enabled flexible reimbursement procedures which incentivize health professionals and encourage the use of technology. Nineteen States now offer reimbursement for telemedicine (Naditz, 2008). Telemedicine services cannot be substituted for face-to-face home visits (although they may be used as a supplement to a required face-to-face visit).

9. Governance of the telemonitoring services

The body which assesses products for telemonitoring, and which sets the level of reimbursement, must be independent and qualified to make the assessments. It is appropriate to include representation of patient interests and industry interests as well as healthcare professionals and payers. It would be appropriate to use the mechanisms established as a result of the Federal Governments review of Health Technology Assessment. Assessments of clinical and comparative effectiveness should be undertaken by reference to appropriately qualified persons.

Decisions of the HTA body should be reviewable and appealable in circumstances where there has been a demonstrable error in a finding. The HTA body would also monitor the effectiveness of the program.

The body would be advisory in that the Minister for Health and Ageing will make the final decision on inclusion of a product and level of reimbursement.

10. Conclusion

There are a wide range of medical devices that can enhance the care of older Australians. Wireless communications and advanced medical technology can be used to respond to the challenges of ageing and chronic disease. Government-
subsidised aged care services are currently provided to approximately 900,000 older Australians (DoHA, 2009). The aim of community care is to aid frail elderly people and those with disabilities to remain either in their own homes or in assisted living arrangements. When care needs can not be met in the community, individuals are transitioned to residential care settings. MTAA strongly supports the establishment of schemes that enable equitable patient access to medical products and technologies. The appropriate provision of Essential Care items and telemonitoring services will decrease emergency room visits, decrease unnecessary hospitalizations, avoid inappropriate transition to residential care and achieve cost savings through maintaining people in their own homes. Monitoring will allow both older frail patients and those in rural and remote areas to receive higher levels of care. Based on overseas models, both the ECL and Telemonitoring services are likely to be highly cost effective. A recent study in Northern Ireland compared the costs of in-hospital care to comparative delivery of out-of-hospital over a year. Out-of-hospital care was 80% less expensive. Five patients could be treated at home for the same price as treating one patient in hospital (Northern Ireland Health Economic Group, 2008). There are a number of examples where care is pushed into hospital settings that could be provided in the home. For example, patients with chronic wounds are most appropriately treated at home (by community nurses) or in the GP’s office (Gross, 2006). Because modern wound care products are not funded, patients end up being treated in (costly) hospital settings.

Telemonitoring is well aligned with Government broadband and electronic health record (EHR) policies. Government strategies such as the National Broadband Network (NBN) will bring broadband into more homes and to remote and rural communities that have not previously had coverage. Network speeds will run at 100 megabits per second and connect other premises with next generation wireless and satellite technologies, offering speeds of 12 megabits per second or more. Next generation wireless and satellite technologies will be able to deliver over 12 megabits per second to people living in more remote parts of rural Australia16. In the future telemonitoring services may be coordinated using Personally Controlled Electronic Health Record (PCEHR)17.

An Australian literature review found consistent reporting of high levels of ‘inappropriate’ bed days in international acute care settings (Poulos & Eagar, 2007). The MTAA predicts that the provision of ECL items and telemonitoring services will decrease the number of potentially preventable hospitalisations (PPHs). These are hospitalizations that could have been avoided had more timely and adequate non-hospital care been provided. In 2007-2008, selected potentially preventable hospitalisations represented 9.3% of all separations in Australian Hospitals. PPHs are often associated with chronic ailments, which could be prevented or managed through effective, timely care (usually non-hospital). These conditions include asthma, angina, diabetes, hypertension, congestive heart failure and chronic obstructive pulmonary disease. These are all conditions that can be managed using appropriate medical consumable items and could be monitored to avoid symptom exacerbations leading to hospitalization. For example, remote monitoring can be used to detect dangerous trends such as weight gain due to fluid retention or lung dysfunction in cardiac and COPD patients.

The paper points out that a particular concern is: “the extent to which some elements of residential care (notably accommodation) are more heavily subsidised than

equivalent care received in the home” (page 19). The MTAA would strongly argue that the provision of care that enables individuals to be treated in the home environment is far more cost effective than all other alternatives. A range of technologies exist to assist and support patients who wish to remain in their own homes. An impediment to access for Australian patients is a lack of physician reimbursement.

The average cost for a visit to an emergency department is $373 (NSW Policy Directive, 2008/2009). In large public hospitals, only 28% (3.8 million) of people who presented to an emergency room were actually referred for treatment or admitted to hospital. This suggests that many people are visiting A&E with conditions that could be best managed in the community. Emergency Room patients are categorized according to need. Category 5 patients are considered non-urgent and usually have minor illnesses or stable chronic conditions such as diabetes with relatively minor complicating symptoms. In 2008-09 these patients accounted for 12% of emergency department presentations. Of 7.2 million presentations during this time period, 864,000 (12%) people may have been better treated using appropriate medical consumables and home monitoring service (Statistics from Hospital Services in Australia, State of our Public Hospitals, June 2010). The average cost of an admission to a public hospital in 2008-09 was $4,471. This covers medical staff, diagnostic services, supplies and support services such as cleaning and meals, medical and drug supplies, allied health services and administration costs. A place in a high level care facility has an average annual cost of $48,550 (or $17,750 in low care facilities) (DoHA, 2009). MTAA is currently consulting with industry to estimate the costs of telemonitoring and address the need for analysis of comparative data.

It is not a major departure from current funding systems to include funding for ECL items or telemonitoring services under current funding schemes designed to assist older Australians to stay in their own homes. Eligibility for either ECL items or telemonitoring services could be determined by current Aged Care Assessment Teams (ACATs), who currently determine eligibility for subsidised community care. MTAA strongly supports schemes which improve access of aged Australians to medical products and telemonitoring services and devices that enable them to maintain an independent life in their community for as long as they are capable of doing so.
References


### Annex A Summary Information on State and Territory aids and appliance programs

<table>
<thead>
<tr>
<th>State/Program</th>
<th>Aids covered</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>QLD – Medical Aids Subsidy Scheme (MASS).</td>
<td>• Communication aids&lt;br&gt;• Continence aids&lt;br&gt;• Daily living aids (e.g. bathroom aids)&lt;br&gt;• Medical grade footwear&lt;br&gt;• Mobility aids&lt;br&gt;• Orthoses&lt;br&gt;• Oxygen cylinders and concentrators</td>
<td><a href="http://www.health.qld.gov.au/mass/">http://www.health.qld.gov.au/mass/</a></td>
</tr>
<tr>
<td>VIC – Victorian Aids and Equipment Program (AEP)</td>
<td>• Non-disposable continence aids&lt;br&gt;• Electrolarynxes and voice prostheses&lt;br&gt;• Electronic communication aids&lt;br&gt;• Environmental control units&lt;br&gt;• Equipment for personal use&lt;br&gt;• Basic home modifications&lt;br&gt;• Lymphoedema compression garments&lt;br&gt;• Mobility aids&lt;br&gt;• Orthoses&lt;br&gt;• Oxygen&lt;br&gt;• Pressure care equipment&lt;br&gt;• Ramps (permanent and portable)&lt;br&gt;• Wheelchairs (manual / electric)&lt;br&gt;• Wigs</td>
<td><a href="http://nps718.dhs.vic.gov.au/ds/disabilitysite.nsf/sectionthree/aids_equipmen?open">http://nps718.dhs.vic.gov.au/ds/disabilitysite.nsf/sectionthree/aids_equipmen?open</a> Further information on programs can be found at: <a href="http://www.wwda.org.au/portaid.htm#gvt">http://www.wwda.org.au/portaid.htm#gvt</a></td>
</tr>
<tr>
<td>NSW – Program of appliances for disabled people. (PADP)</td>
<td>• Communication aids&lt;br&gt;• Aids to nutrition&lt;br&gt;• Alarms&lt;br&gt;• Beds and sleeping equipment&lt;br&gt;• Mobility aids&lt;br&gt;• Pain management aids&lt;br&gt;• Pressure garments,&lt;br&gt;• Orthoses&lt;br&gt;• Toileting and showering aids&lt;br&gt;• Transfer aids&lt;br&gt;• Continence aids&lt;br&gt;• Continuous Positive Airways Pressure (CPAP) devices</td>
<td><a href="http://www.health.nsw.gov.au/policies/pdf/2005/PD2005_563.html">http://www.health.nsw.gov.au/policies/pdf/2005/PD2005_563.html</a></td>
</tr>
<tr>
<td>WA- Community Aids and Equipment program (CAEP)</td>
<td>Loan of:&lt;br&gt;• Mobility aids&lt;br&gt;• Seating equipment&lt;br&gt;• Walking aids&lt;br&gt;• Orthoses&lt;br&gt;• Transfer aids&lt;br&gt;• Bed equipment&lt;br&gt;• Personal care aids&lt;br&gt;• Prostheses</td>
<td><a href="http://www.disability.wa.gov.au/DSC:STANDARD::pc=PC_90385">http://www.disability.wa.gov.au/DSC:STANDARD::pc=PC_90385</a></td>
</tr>
</tbody>
</table>
| Equipment Scheme (CES) | Mobility aids  
| Transfer devices  
| Self-care aids  
| Seating and sleeping aids  
| Surgical footwear  
| Continence aids  
| Communication devices  
| Home modifications  
| Respiratory aids  
| Lymphoedema compression bandages | view.php?id=352 |
| ACT – ACT Equipment Scheme (ACTES) | Continence aids  
| Wheelchairs and scooters  
| Prosthesis  
| Walking aids  
| Wigs  
| Personal aids  
| NT – Territory Independence and Mobility Equipment (TIME) Scheme | Loan of:  
| Mobility aids  
| Incontinence aids  
| Personal care aids  
| Home modifications  
| Respiratory or breathing aids  
| Other-such as feeding equipment | http://www.nt.gov.au/health/comm_s_vs/aged_dis_ccs/time/index.shtml |
## Annex B Essential Care List Costs

<table>
<thead>
<tr>
<th>ECL Category</th>
<th>ECL least conservative cost (may include device)</th>
<th>ECL most conservative cost (consumables/rental only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen supplies/consumables</td>
<td>$13,766 x $3,945 (average cost of concentrator and $200 consumables) = $54,306,870</td>
<td>$13,766 x $1,700 = $23,402,200</td>
</tr>
<tr>
<td>Compression hosiery, bandages and garments for lymphoedema</td>
<td>$300,000 (assumes funding for patients with all forms of primary and secondary lymphoedema) x $300 = $90,000,000</td>
<td>$10,000 (this number assumes funding for chronic patients only) x $300 = 3,000,000</td>
</tr>
<tr>
<td>Continenance products</td>
<td>$18,000 x $610 [19] (this is the average of the subsidies for each state/territory incorporating the $490 from CAAS = $10,980,000</td>
<td>$18,000 x $490 = $8,820,000</td>
</tr>
<tr>
<td>Modern wound care devices (including wound dressings)</td>
<td>200,000 (chronic wounds), includes venous leg ulcers x $259[19] = $51,800,000</td>
<td>Chronic ulcers: 200,000 x $154[22] = $30,800,000</td>
</tr>
<tr>
<td>Breast prosthetics (non-implantable)</td>
<td>$6,200,000 (allocated pa)</td>
<td>$6,200,000 (allocated pa)</td>
</tr>
<tr>
<td>Insulin pumps and continuous flow pumps, and consumables (pens, strips, pump consumables)</td>
<td>~$8,444,233 per year allocated for IPCs[21]. The cost of covering additional IPCs for pump users is: batteries ($84 pa) + lancets ($24 pa) + skin adhesives and swabs ($335 pa) [5,000 x $443 = $2, 215,000]. The cost of covering 2,500[22] pumps at $8,000 each = $20,000,000 Total: $30,659,233</td>
<td>~$8,444,233 per year allocated for IPCs. The cost of covering additional IPCs for pump users is: batteries ($84 pa) + lancets ($24 pa) + skin adhesives and swabs ($335 pa) [5,000 x $443 = $2, 215,000]. Total: $10,659,233</td>
</tr>
<tr>
<td>CPAP/sleep apnoea devices</td>
<td>16,000[24] x $1,800 (machine) + $350 (consumables only) = $34,400,000</td>
<td>16,000 x $350 (consumables only) = $5,600,000</td>
</tr>
<tr>
<td>Laryngitic products</td>
<td>500 x $5,000 (speech generating devices and accessories) = $2,500,000</td>
<td>500 x $1200 (basic artificial larynx and accessories inc batteries) = $600,000 Or 500 x $450 (voice prosthesis) = $225,000 Consumables[25] only; shower protector ($60), stoma cover (n=50, $65), laryngectomy tubes (n=4, $265), cleaning kit ($66) = 500 x $456 = $228,000</td>
</tr>
<tr>
<td>Home dialysis devices, consumables and set-up costs</td>
<td>10,062 x $38,424 = $386,622,288</td>
<td>10,062 x $12,727 = 128,059,074</td>
</tr>
<tr>
<td><strong>TOTALS</strong></td>
<td><strong>$667,468,391</strong></td>
<td><strong>$216,768,507</strong></td>
</tr>
</tbody>
</table>

---

21. NDSS statistics.
22. Approximate number of new users of insulin pumps per year.
23. NDSS statistics.
24. In 2004 there were 68,000 full PSGS performed in Australia. If you assume 66% were diagnostic, half went onto CPAP and most (70%) stayed on it, the CPAP figure would be 16,000.
## Annex C Essential Care List Costs Savings

<table>
<thead>
<tr>
<th>ECL Category</th>
<th>Cost savings associated with reducing hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen supplies/consumables</td>
<td>Of 13,766 assume 9.3%(^{26}) ((n=1,280)) will be inappropriately admitted to hospital at an average cost of $1,718 (average DRG cost, public; $1,648 average DRG cost, private)(^{27}) = savings of $2,199,040.</td>
</tr>
<tr>
<td>Compression hosiery, bandages and garments for lymphoedema</td>
<td>In 2007-08 there were 3,274(^{28}) separations (2,347 public, 927 private) for enlarged lymph nodes and oedema. The cost of treating circulatory disorders is $7,850 (average DRG cost, public) and $6,202 (average DRG cost, private) = $24,173,204. Assume 9.3% ((n=304)) will be inappropriately admitted to hospital = savings of $2,248,108.</td>
</tr>
<tr>
<td>Continence products</td>
<td>In 2007-08, there were 3,862 separations (1,403 public, 2,459 private) for faecal and urinary incontinence with an average cost of $1,648(^{29}) per separation = $15,003,870. Assume 9.3% ((n=359)) in inappropriate admissions = savings of $1,395,360.</td>
</tr>
<tr>
<td>Modern wound care devices</td>
<td>In 2007-08 there were 72,599 separations for skin ulcers, open wounds and burns (63,202 public, 9,397 private) at a cost of $3,885 per separation = $282,047,115. Assume 9.3% ((n=6,751)) inappropriate admissions = savings of $26,230,382.</td>
</tr>
<tr>
<td>Breast prosthetics</td>
<td>n/a (2007-08 there were 10,568 separations for breast cancer surgery).</td>
</tr>
<tr>
<td>Insulin pumps and continuous flow pumps, and consumables</td>
<td>In 2007-08 there were 237,119(^{30}) separations for potentially preventable diabetes complications at a cost of $8,603, (average DRG cost, public)(^{31}) or $7,017 (average DRG cost, private) per separation. Average = $7,810 = $1,851,899,390. Assume 9.3% ((n=22,052)) inappropriate admissions = savings of $172,226,643.</td>
</tr>
<tr>
<td>CPAP/sleep apnoea devices</td>
<td>In 2007-2008 there were 43,277 (7,257 public, 36,020 private) hospital sleep studies(^{32}). There were 36,135 hospitalizations for sleep apnoea (7,598 public, 28,537 private) at a cost of $1,394 (average DRG cost, public) or $653 (average DRG cost, private) – per separation(^{33}) = $29,226,273. Assume 9.3% inappropriate admissions ((n= 3,361)) = savings of $2,718,043.</td>
</tr>
<tr>
<td>Laryngitic products</td>
<td>In 2007-08 there were 242 laryngectomy procedures performed (198 public, 44 private) and 319 application, insertion or removal procedures on the larynx (203 public, 116 private).</td>
</tr>
<tr>
<td>Home dialysis devices, consumables and set-up costs</td>
<td>In 2007-08 there were 990,787(^{34}) (825,331 public, 165,456 private) separations for dialysis care and 9,397 (5,728 public, 3,615 private) separations for peritoneal dialysis. These cost $470,480,890 (average DRG costs, public) and $72,832,110 (average DRG costs, private) = $543,313,000. Assume 9.3% ((n=92,184)) inappropriate admissions = savings of $50,528,109.</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$257,545,685</strong></td>
</tr>
</tbody>
</table>

---

\(^{26}\) 9.3% preventable separations for chronic conditions: AIHW. Separation statistics for selected potentially preventable hospitalisations for chronic conditions for all states and hospitals, 2007–08.


\(^{28}\) AIHW: Selected separation statistics(a) for all principal diagnoses in 3-character ICD-10-AM groupings, public hospitals, Australia, 2007–08.


\(^{30}\) AIHW: Separation statistics for selected potentially preventable hospitalisations for chronic conditions for all states and hospitals, 2007–08.


\(^{32}\) Selected separation statistics(a) for procedures in ACHI blocks, private hospitals, Australia, 2007-08.


\(^{34}\) AIHW: Selected separation statistics for all principal diagnoses in 3-character ICD-10-AM groupings, public and private hospitals, Australia, 2007–08.
Annex D Representation of Supply Chain (UK)

* In this diagram a vertically integrated manufacturer refers to an organization that is both a supplier and appliance contractor.
### Annex E Clinical Evidence for Telemonitoring

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study type</th>
<th>Patient population</th>
<th>Duration</th>
<th>Type of intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chumbler et al. (2009)</td>
<td>Retrospectively matched controlled comparison using propensity scores</td>
<td>n=774 diabetes patients: intervention group n=387, UC n=387</td>
<td>4 years</td>
<td>Veterans Health Administration (VHA) care coordination/ home-telehealth (CC/HT) program using Health Buddy as communication device for education and monitoring of symptoms and health status; daily data monitoring</td>
<td>- The intervention group had a reduction in 4-year all-cause mortality: hazard ratio = 0.69, ( p &lt; 0.05 ) and an increase in mean survival time (1,348 days versus 1,278 days, ( p &lt; 0.05 ))</td>
</tr>
</tbody>
</table>
| Crossley et al. (2008) | RCT including from 150 US sites | n=2,000 patients implanted with an implantable cardiac device, randomized to UC or TM | 15 months | Patients remotely monitored using wireless telemetry devices, including wireless alerts. Paper describes study, media alert outlines early results | - The median time to clinical decision was significantly reduced in the TM group (\( p < .001 \))  
- There was a significant decrease in mean length of hospital stays in the TM group (\( p = .002 \))  
- Hospital costs were reduced                                                                                                                                                                                      |
| Darksins et al. (2008) | Non-controlled pre and post evaluation study | n=17,025 veterans with diabetes, COPD, heart failure, diabetes hypertension and mental health problems | 12 months | Veterans Health Administration: the national Care Coordination/Home Telehealth (CCHT) aids independent living through implementing home telehealth, health informatics and disease management technologies | - The intervention was associated with a 25% reduction in numbers of bed days of care; a 19% reduction in numbers of hospital admissions and a mean satisfaction score rating of 86%                                                                 |
| Giordano et al. (2009) | multicenter (n=5) RCT | n=460 patients with chronic heart failure randomized to TM (n=230) or UC (n=230) | 1 year   | Two strategies: home-based TM or UC. The UC group were referred to a primary care physician. The TM group portable advice that transferred data to a station that had a nurse or a doctor available 24 h, 7 days/week. The nurse and cardiologist met weekly. | - Monitored patients had a 50% lower risk of heart failure related readmission (\( p < 0.001 \)), a 55% reduction in cardiovascular mortality (\( p = 0.06 \)), and a 31% decrease in episodes of hemodynamic instability (\( p < 0.001 \))  
- Cost of hospital readmission was 35% lower in the TM group (\( p = 0.01 \))                                                                                                                                     |
| Goernig et al. (2009)  | RCT             | n=95 patients, 5 with suspected paroxysmal                                           | 1 year   | TM data from a mobile 12 channel ECG, heart rate and BP were transmitted daily; patients were | - Compliance was high  
- The TM group had fewer hospitalizations (43%, \( p < 0.01 \)), a 68% decrease in hospital days and a 76% decrease in length of hospital stay                                                                                     |
<table>
<thead>
<tr>
<th>Authors</th>
<th>Study Design</th>
<th>Setting</th>
<th>Duration</th>
<th>Intervention Description</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goldberg et al. (2003)</td>
<td>Large multicenter, randomized trial: Weight Monitoring in Heart Failure Trial (WHARF)</td>
<td>Setting: 16 heart failure centres across the U.S. 280 patients were randomized into TM (n=138) or UC (n=142)</td>
<td>6 months</td>
<td>The TM group received the AlereNet system: electronic scales and an individualized symptom response system that is linked to a computerized database and monitored by cardiac nurses. Data were reviewed daily and patients contacted if necessary</td>
<td>- No differences in hospitalization rates were found. There was a 56.2% reduction in mortality (p=&lt;.01) for patients in the TM group</td>
</tr>
<tr>
<td>Koff et al. (2009)</td>
<td>RCT (single centre)</td>
<td>n=400 COPD patients: intervention group n=270, UC n=130</td>
<td>9 months</td>
<td>Proactive Integrated Care including education, self-management techniques and remote home monitoring with Health Buddy; monitoring from Mon-Fri for changes in symptoms, SpO², FEV1 and steps in 6 min walk test</td>
<td>- The TM group had significant improvements in health-related QOL and a decrease in mortality (p=&lt;0.04); - were reductions in critical care utilizations and gross costs (depending on hospital reimbursement rates)</td>
</tr>
<tr>
<td>Mabo et al. (2010)</td>
<td>RCT, multicentre, prospective study (COMPAS)</td>
<td>Examined the safety and efficacy of long-term pace maker follow-up. 538 patients randomized to TM (n=269) or UC (n=269)</td>
<td>18 months</td>
<td>Home monitoring of implanted device. Cardiomessenger Mobile patient device transmits data via a cellular network for monitoring</td>
<td>-TM reduced office visits for follow-up and facilitated the early detection of clinical anomalies such as atrial arrhythmias - The TM group had a reduction in atrial arrhythmia events and related strokes</td>
</tr>
<tr>
<td>Polisena et al. (2010)</td>
<td>Literature review on 21 studies of home TM for congestive heart failure</td>
<td>21 studies (including n=3,082 patients)</td>
<td>30 days-1 year</td>
<td>Wide range of both home TM interventions and usual care in the selected studies</td>
<td>- Impressive results, TM was associated with a reduction in mortality (risk ratio = 0.64) vs. to usual care</td>
</tr>
<tr>
<td>Stone et al. (2010)</td>
<td>Randomized study</td>
<td>Veterans with diabetes (n=150) were assigned to active home TM (n=73) or a monthly</td>
<td>3 &amp; 6 months</td>
<td>The TM group transmitted blood glucose, BP and weight data to a nurse using a telehealth monitor. The practitioner adjusted medications for glucose, BP and lipid control, based on</td>
<td>- While both interventions improved glycemic control, the TM group showed significantly larger decreases in HbA₁c at 3 (1.7 vs. 0.7%) and 6 months (1.7 vs. 0.8%; p=&lt;0.001 for each), the most</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Patient Characteristics</td>
<td>Follow-up</td>
<td>Pre-established Guidelines</td>
<td>Improvement Occurred at 3 Months</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>-----------</td>
<td>---------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Varma et al. (2010)</td>
<td>RCT</td>
<td>$n=1,339$ patients were randomized to TM or conventional follow-up. All patients had implanted cardioverter defibrillators</td>
<td>1 year</td>
<td>The TM group were remotely monitored. Conventional patients were evaluated with office visits only. Actionable evaluations included clinically significant reprogrammable changes, medication changes, lead/generator revision</td>
<td>- This was the first large scale clinical trial of ICD follow-up using remote monitoring - Arrhythmias were the commonest cause for event notifications - Total in-office visits were reduced 45% in the TM group - Results have led to the approval of the system by the FDA</td>
</tr>
<tr>
<td>Vitacca et al. (2009)</td>
<td>RCT (single centre)</td>
<td>$n=240$ respiratory patients (101 with COPD) were randomized to TM or UC</td>
<td>12 months</td>
<td>Data (oxygen saturation measured by pulse oximetry) were monitored. Nurses were available 40 hours/week for consultation. A call centre received data 24 h per day. An on-duty pulmonologist was contacted if needed</td>
<td>- The TM group had a significant decrease in hospitalizations (-36%), fewer urgent GP calls (-65%) and fewer ER admissions (-71%)</td>
</tr>
<tr>
<td>Woodend et al. (2008)</td>
<td>RCT</td>
<td>$n=249$ patients were randomly allocated to TM or usual care</td>
<td>3 months, 1 year</td>
<td>Daily transmission of weight and BP, and periodic transmission of 12-lead ECG. Video conferences were held at least weekly with each patient and included assessment and self-care education by the care nurse</td>
<td>- At 3 months TM reduced the number of hospital readmissions ($p=.02$) and days spent in hospital for patients ($p=.04$) with angina and improved QOL - At 1 year, patients with angina had significantly fewer hospital admissions than patients receiving UC ($p=.02$)</td>
</tr>
</tbody>
</table>

TM=telemonitoring; RCT=randomized controlled trial; UC = usual care; GP=general practitioner; ER=emergency room; COPD=chronic obstructive pulmonary disease; QOL=quality of life; CHF=chronic heart failure; PTSD=post traumatic stress disorder; HF=heart failure.
### Annex F Cost Effectiveness Outcomes for Telemonitoring

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study type</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alwan et al. (2007)</td>
<td>Case-controlled study of passive health-status monitoring. Monitoring systems were installed in the homes of 21 patients. Heart rate, breathing rate, key alert conditions and activities of daily living (ADL) were monitored.</td>
<td>There was a decrease in hospital days ($p&lt;.01$), a reduction in billable interventions ($p=.040$) and a decrease in the estimated cost of care of $46,566$ ($p=.034$). Monitoring reduced cost of care to payers and had a positive impact on staff efficiency.</td>
</tr>
<tr>
<td>Armstrong et al. (2007)</td>
<td>Compared the costs of a face-to-face dermatology consultation with an interactive teledermatology consultation. Included data from 451 patients.</td>
<td>The total cost of the standard consultation was $346$ per hour and the total hourly cost of the tele-consultation was $274$ per hour. The two main factors contributing to lower cost were low costs of technology and the decreased cost of clinic space.</td>
</tr>
<tr>
<td>Dansky et al. (2001)</td>
<td>RCT: $n=171$ diabetic patients were randomly assigned to either an intervention ($n=86$) or a control group ($n=85$). The TM group received nursing visits and virtual visits and monitoring via medical sensors (a sphygmomanometer for BP and a stethoscope for heart rate). The UC group received nurse visits only.</td>
<td>A number of positive clinical outcomes were translated into cost savings. Fewer TM patients needed recertification after 60 days ($p&lt;.01$), 63.7% of TM patients were discharged to home vs. 39% of the UC group ($p=0.01$), only 10% of TM patients were hospitalized during the intervention vs. 28% of UC patients ($p=0.05$). The authors estimated hospitalization costs to be $87,327$ for TM patients and $232,872$ UC patients.</td>
</tr>
<tr>
<td>Darkins et al. (2008)</td>
<td>Veterans Health Administration: the national Care Coordination/Home Telehealth (CCHT) program. Included $n=17,025$ veterans. CCHT aids independent living. Monitoring reduces hospitalizations and bed days of care</td>
<td>Large cost savings were achieved. The CCHT costs $1,600$ per patient per annum. This is much lower than the direct cost of VHA’s home-based primary care services of $13,121$ (VHA internal data 2008) per annum, and nursing home care rates of $77,745$ per patient per annum.</td>
</tr>
<tr>
<td>Litzinger et al. (2007)</td>
<td>Assessed video teleconferencing for wound care over a 2 year period. $n=35$ patients were enrolled and received multiple wound care evaluations. The technology can be used for patients with chronic wounds who are unable to leave their home to receive care.</td>
<td>A total of 421 hours of nursing visits were saved and 916 hours of travel time avoided. There was an overall saving of 1,338 hours of time and a cost reduction of $42,175$. After all costs were considered the net saving of the program was $25,208$.</td>
</tr>
<tr>
<td>Maiolo et al. (2003)</td>
<td>Assessed $n=20$ severe COPD patients and $n=20$ matched controls who were monitored using sensors connected to a monitoring device and a transmitting unit. Patient pulse-oximetry and heart rate were monitored twice a week and patients had face-to-face medical visits every 3 months.</td>
<td>At 12 months follow-up the study found that monitoring resulted in a lower number of hospital visits, a decrease in the number of acute home exacerbations and a cost saving of $1,739$ per patient (a 17% gain).</td>
</tr>
<tr>
<td>Source: Meyer, Kobb &amp; Ryan (2002)</td>
<td>Assessed case management and telehealth versus usual care in 791 veterans with chronic diseases (heart failure, COPD, diabetes and hypertension) one year after telehealth (the dial up device included surveys, blood sugar, chest pain, weight and blood pressure measures, a camera was used to photograph diabetic wounds)</td>
<td>Patients in the TM group were 7.7% less likely to be admitted to a nursing home, ER visits were reduced by 40%, hospital admissions by 63%, and reduction in hospital bed days of care by 60%. There were similar reductions in nursing home care.</td>
</tr>
<tr>
<td>Source: Noel et al. (2004)</td>
<td>n=104 patients with lung disease, heart failure and/or diabetes were randomized to a TM or UC group for 6-12 months. The study assessed whether integrated home telehealth with electronic medical records reduces cost and increases QOL outcomes. The TM group were provided with peripheral devices to monitor vital signs and questionnaires to evaluate QOL. Out-of-range data triggered alerts.</td>
<td>At 6 months, the TM group had a significant decrease in bed days of care (p&lt;.01), urgent clinic and ER visits (p=.023), and A1C levels (p&lt;.01). The cost reduction for the intervention group was ~5%. Time and cost saving strategies were generated by collecting data using peripheral devices, automatic data entry and alerts, patient education and feedback, eliminating unnecessary home visits and early detection, diagnosis, and intervention.</td>
</tr>
<tr>
<td>Source: Scalvini et al. (2005)</td>
<td>Assessed home-based TM in 426 patients (n=230 TM, n=196 UC). TM consisted of trans-telephonic follow-up, ECG monitoring, tele-assistance (via a call centre) and medical visits. Patients were followed over 1 year.</td>
<td>The TM group had a significant reduction in hospitalizations vs. the usual care group and an increase in QOL. The total costs were lower in the TM group (€107,494) vs. the UC group (€140,874) at 1 year follow-up.</td>
</tr>
<tr>
<td>Source: Seto (2008)</td>
<td>Systematic review of cost effectiveness of telemonitoring vs UC for heart failure. Only articles describing systems with a component of home physiological measurements were included (n=11)</td>
<td>Telemonitoring resulted in costs savings in all of the studies (range = 1.6% to 68.3%). Cost reductions were associated with reduced hospitalization expenditure. The only study to assess indirect costs found that travel costs were 3.5% lower in the telemonitoring group.</td>
</tr>
<tr>
<td>Source: Vontetsianos et al. (2005)</td>
<td>Adopted home-telecare software that included real-time home-video conferencing with the hospital via the patient’s television to monitor 18 patients with advanced COPD. A nurse visited the home and monitored vital signs (ECG, blood pressure, spirometry and oximetry)</td>
<td>Home monitoring was associated with a decrease in hospital days and ER visits. Total overall costs were lower. The cost of hospital days in the 12 months before the intervention was €515 per month and the cost of hospital days in the 9 months after the intervention was €138).</td>
</tr>
</tbody>
</table>